Enanta downgraded to Perform on hep C headwinds at Oppenheimer
Oppenheimer analyst Jay Olson downgraded Enanta to Perform from Outperform following quarterly results and in the face of HCV headwinds. The analyst lowered his price target on the shares to $100 from $135.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.